IGM Biosciences (IGMS) FY Earnings Call Presentation

Company Overview and Strategy - IGM Biosciences is a global leader in developing IgM antibodies for therapeutic use, focusing on oncology, inflammation, and infectious diseases[3,4,5] - The company's strategy involves advancing product candidates, increasing R&D efforts, expanding manufacturing capabilities, expanding the intellectual property portfolio, and participating in commercialization if approved[6] - IGM Biosciences has a proprietary IgM antibody technology with 38 patent families[7] - As of December 31, 2021, IGM Biosciences had $230 million in cash and investments[7] IgM Antibody Technology and Pipeline - IgM antibodies have unique structural attributes compared to IgG, leading to superior total binding power[8] - IGM's pipeline includes programs in oncology and infectious diseases, with several candidates in preclinical and clinical stages[15] - IGM-2323 (CD20 x CD3) is in Phase 2 development for NHL and CLL[15] - IGM-8444 (DR5) is in Phase 1 development for solid and hematologic malignancies[15] - IGM-6268 (SARS-CoV-2) is in Phase 1 development as a COVID-19 target neutralizer[15] Clinical Data and Development - IGM-2323 Phase 1 safety data showed low levels of CRS and neutropenia[24] - IGM-2323 Phase 1 activity showed encouraging response rates at the 100 mg dose in DLBCL and FL[25] - IGM-8444 Phase 1 dose escalation clinical trial has treated 38 patients as of January 7, 2022, with 13 patients remaining on treatment and no discontinuations for drug-related safety reasons[53] - IGM-6268 showed significantly improved potency in SARS-CoV-2 neutralization assay when converted from IgG[75] Anticipated Catalysts in 2022 - Multiple catalysts are anticipated in 2022, including initial Phase 2 data for IGM-2323, initial Phase 1 combination data for IGM-8444, initial Phase 1 data for IGM-6268, and Phase 1 initiation for IGM-7354 and IGM-2644[81]